Observational Study About Patients Diagnosed With NAFLD

Status Recruiting

Clinical Trial Summary

Nonalcoholic fatty liver disease (NAFLD) is the most common condition affecting the liver, owing to its association with obesity and the metabolic syndrome. The largest study to date using magnetic resonance spectroscopy to quantify liver triglyceride (TG) content showed that approximately 33% of individuals have hepatic steatosis. NAFLD encompasses a continuum of histological findings that starts with steatosis that can progress to nonalcoholic steatohepatitis (NASH), which is characterized by inflammation and cell death, and eventually cirrhosis. Given the large number of individuals afflicted with this condition, there is a clear need to develop effective and safe therapies to treat NAFLD.

Clinical Trial Description

Patients with NAFLD were recruited in the current study and divided into NAFLD group, and NASH group. The researchers will collect various clinical examination indexes of the subjects in the process of diagnosis and treatment, including but not limited to ALT, AST, TG, TC, etc. Characteristic and prognosis of patients will be recorded. The serum, feces, urine and liver (if necessary) samples of all subjects will be taken after enrollment and stored for probably testing in the future. This study has no additional intervention and treatment for subjects. ;

Study Design

Related Conditions & MeSH terms

Fatty Liver
Liver Diseases
Non-alcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease

Clinical Trial Details

NCT number	NCT05625750
Study type	Observational
Source	Xiangya Hospital of Central South University
Contact	Yan Huang
Phone	+86 13874854142
Email	ganrankedrhyan@163.com
Status	Recruiting
Phase
Start date	April 27, 2022
Completion date	April 27, 2027

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT06138327` - A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria	Phase 1
Completed	`NCT01045499` - LAGB as a Treatment for Morbid Obesity in Adolescents	N/A
Completed	`NCT03674476` - An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function	Phase 1
Not yet recruiting	`NCT05495139` - Gastric Bypass Stent Small-Sample-Size Study For Nonalcoholic Fatty Liver Disease	N/A
Completed	`NCT04988204` - Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease	N/A
Recruiting	`NCT04369521` - Evaluation of the Effects of a Low Free Sugar Diet in Patients With Nonalcoholic Fatty Liver Disease	N/A
Completed	`NCT01934777` - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis	Phase 3
Enrolling by invitation	`NCT00983463` - Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)
Recruiting	`NCT00658164` - Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores	Phase 3
Recruiting	`NCT02148471` - Fatty Acids, Genes and Microbiota in Fatty Liver	N/A
Completed	`NCT06441409` - Serum Ferritin Levels and Metabolic Dysfunction Associated Steatotic Liver Disease	N/A
Completed	`NCT03656744` - A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)	Phase 2
Not yet recruiting	`NCT01735799` - THE ASSOCIATION BETWEEN FATTY LIVER (NAFLD) DISEASE AND PCOS	N/A
Completed	`NCT01446276` - Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver Disease	N/A
Completed	`NCT00930384` - A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis	N/A
Recruiting	`NCT02469272` - Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study	Phase 1
Completed	`NCT02132780` - Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease	N/A
Completed	`NCT01399645` - Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes	Phase 2
Terminated	`NCT01355575` - Rifaximin in Fatty Liver Disease	Phase 4
Completed	`NCT01210989` - Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis	N/A